{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:32:52Z","timestamp":1792056772955,"version":"4.4.0"},"reference-count":190,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40265-020-01256-5","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T12:02:46Z","timestamp":1580385766000},"page":"99-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases"],"prefix":"10.1007","volume":"80","author":[{"given":"HoUng","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-4412","authenticated-orcid":false,"given":"Rieke","family":"Alten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Avedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-054X","authenticated-orcid":false,"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gomoll\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Greveson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0122-7234","authenticated-orcid":false,"given":"Jonas","family":"Halfvarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-2914","authenticated-orcid":false,"given":"J\u00f8rgen","family":"Jahnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JongHyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souzi","family":"Makri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-2005","authenticated-orcid":false,"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3073","authenticated-orcid":false,"given":"Rene","family":"Westhovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-403X","authenticated-orcid":false,"given":"Ji Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"1256_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","volume":"4","author":"P Rein","year":"2017","unstructured":"Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4:247\u201361.","journal-title":"Rheumatol Ther"},{"key":"1256_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","volume":"18","author":"P Sarzi-Puttini","year":"2019","unstructured":"Sarzi-Puttini P, Ceribelli A, Marotto D, et al. Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev. 2019;18:583\u201392.","journal-title":"Autoimmun Rev"},{"key":"1256_CR3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","volume":"14","author":"S Ben-Horin","year":"2016","unstructured":"Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14:1685\u201396.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1256_CR4","unstructured":"Kent D, Rickwood S, and Di Biase S. Disruption and maturity: the next phase of biologics. 2017; https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/nemea\/uk\/disruption_and_maturity_the_next_phase_of_biologics.pdf?_=1518214264988. Accessed 17 Dec 2019."},{"key":"1256_CR5","unstructured":"van den Hoven A. Biosimilar medicines clinical use: an experience-based EU perspective. 2017; https:\/\/www.medicinesforeurope.com\/docs\/20170713%20-%20Biosimilar%20Medicines%20Group,%20EU%20experience-AVH-US%20FDA%20Adcom.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR6","unstructured":"IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. 2016; https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/delivering-on-the-potential-of-biosimilar-medicines.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR7","unstructured":"IQVIA. The impact of biosimilar competition in Europe. 2018; https:\/\/ec.europa.eu\/docsroom\/documents\/31642. Accessed 17 Dec 2019."},{"key":"1256_CR8","unstructured":"Jacoby R, Smith E, Wilkins D, et al. Winning with biosimilars. Opportunities in global markets. 2016; https:\/\/www2.deloitte.com\/content\/dam\/Deloitte\/us\/Documents\/life-sciences-health-care\/us-lshc-biosimilars-whitepaper.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR9","doi-asserted-by":"crossref","unstructured":"Mulcahy AW, Hlavka JP, and Case SR. Biosimilar cost savings in the United States: initial experience and future potential. 2017; https:\/\/www.rand.org\/pubs\/perspectives\/PE264.html. Accessed 17 Dec 2019.","DOI":"10.7249\/PE264"},{"key":"1256_CR10","unstructured":"QuintilesIMS. The impact of biosimilar competition in Europe. 2017; http:\/\/ec.europa.eu\/growth\/content\/impact-biosimilar-competition-price-volume-and-market-share-update-2017-0_en. Accessed 17 Dec 2019."},{"key":"1256_CR11","doi-asserted-by":"publisher","first-page":"e000710","DOI":"10.1136\/rmdopen-2018-000710","volume":"4","author":"B Glintborg","year":"2018","unstructured":"Glintborg B, Sorensen J, Hetland ML. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open. 2018;4:e000710.","journal-title":"RMD Open"},{"key":"1256_CR12","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, S\u00f8rensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR13","doi-asserted-by":"crossref","unstructured":"Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis 2019;78:192.","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"1256_CR14","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2016.01.002","volume":"45","author":"A Al-Sabbagh","year":"2016","unstructured":"Al-Sabbagh A, Olech E, McClellan JE, et al. Development of biosimilars. Semin Arthritis Rheum. 2016;45:S11\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"1256_CR15","doi-asserted-by":"crossref","unstructured":"Vulto AG and Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford) 2017;56:iv14\u201329.","DOI":"10.1093\/rheumatology\/kex278"},{"key":"1256_CR16","doi-asserted-by":"crossref","unstructured":"Tsuruta LR, Lopes dos Santos M, and Moro AM. Biosimilars advancements: moving on to the future. Biotechnol Prog 2015;31:1139\u201349.","DOI":"10.1002\/btpr.2066"},{"key":"1256_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/conmed-2017-100003","volume":"1","author":"J Isaacs","year":"2017","unstructured":"Isaacs J, Goncalves J, Strohal R, et al. The biosimilar approval process: how different is it? Consider Med. 2017;1:3\u20136.","journal-title":"Consider Med"},{"key":"1256_CR18","unstructured":"US Food and Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. Guidance for industry. 2019; https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm291134.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR19","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014; http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/01\/WC500180219.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR20","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015; https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm291128.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR21","doi-asserted-by":"crossref","unstructured":"Declerck P and Farouk Rezk M. The road from development to approval: Evaluating the body of evidence to confirm biosimilarity. Rheumatology (Oxford) 2017;56:iv4\u2013iv13.","DOI":"10.1093\/rheumatology\/kex279"},{"issue":"Suppl 1","key":"1256_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.drudis.2015.03.011","volume":"20","author":"LA Bui","year":"2015","unstructured":"Bui LA, Hurst S, Finch GL, et al. Key considerations in the preclinical development of biosimilars. Drug Discov Today. 2015;20(Suppl 1):3\u201315.","journal-title":"Drug Discov Today"},{"key":"1256_CR23","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","volume":"120","author":"M Weise","year":"2012","unstructured":"Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111\u20137.","journal-title":"Blood"},{"key":"1256_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrd3746","volume":"11","author":"SA Berkowitz","year":"2012","unstructured":"Berkowitz SA, Engen JR, Mazzeo JR, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11:527\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"1256_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jpba.2018.08.024","volume":"161","author":"V H\u00e1da","year":"2018","unstructured":"H\u00e1da V, Bagdi A, Bihari Z, et al. Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: a viewpoint from the biosimilar industry. J Pharm Biomed Anal. 2018;161:214\u201338.","journal-title":"J Pharm Biomed Anal"},{"key":"1256_CR26","unstructured":"United States Food & Drug Administration. Guidance for industry: E9 statistical principles for clinical trials. 1998; https:\/\/www.fda.gov\/media\/71336\/download. Accessed 17 Dec 2019."},{"key":"1256_CR27","unstructured":"European Medicines Agency. Note for guidance on statistical principles for clinical trials. 1998; https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR28","unstructured":"US Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness. 2016; https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/non-inferiority-clinical-trials. Accessed 17 Dec 2019."},{"key":"1256_CR29","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.semarthrit.2015.04.002","volume":"44","author":"R Alten","year":"2015","unstructured":"Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 2015;44:S2\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"1256_CR30","doi-asserted-by":"publisher","first-page":"e000154","DOI":"10.1136\/rmdopen-2015-000154","volume":"2","author":"Z Lai","year":"2016","unstructured":"Lai Z, La Noce A. Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. RMD Open. 2016;2:e000154.","journal-title":"RMD Open"},{"key":"1256_CR31","doi-asserted-by":"crossref","unstructured":"Jairath V, Zou GY, Parker CE, et al. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:Cd011572.","DOI":"10.1002\/14651858.CD011572.pub2"},{"key":"1256_CR32","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/apt.14672","volume":"47","author":"C Ma","year":"2018","unstructured":"Ma C, Guizzetti L, Panaccione R, et al. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1578\u201396.","journal-title":"Aliment Pharmacol Ther"},{"key":"1256_CR33","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613\u201320.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR34","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","volume":"393","author":"BD Ye","year":"2019","unstructured":"Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699\u2013707.","journal-title":"Lancet"},{"key":"1256_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7326\/M18-1512","volume":"170","author":"A Meyer","year":"2019","unstructured":"Meyer A, Rudant J, Drouin J, et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study. Ann Intern Med. 2019;170:99\u2013107.","journal-title":"Ann Intern Med"},{"key":"1256_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/apt.15323","volume":"50","author":"A Meyer","year":"2019","unstructured":"Meyer A, Rudant J, Drouin J, et al. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther. 2019;50:269\u201377.","journal-title":"Aliment Pharmacol Ther"},{"key":"1256_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000453343","volume":"35","author":"M Kolar","year":"2017","unstructured":"Kolar M, Duricova D, Bortlik M, et al. Infliximab biosimilar (Remsima\u2122) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis. 2017;35:91\u2013100.","journal-title":"Dig Dis"},{"key":"1256_CR38","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1517\/14712598.2015.1064893","volume":"15","author":"K Farkas","year":"2015","unstructured":"Farkas K, Rutka M, Balint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn\u2019s disease and ulcerative colitis\u2014experiences from a single center. Expert Opin Biol Ther. 2015;15:1257\u201362.","journal-title":"Expert Opin Biol Ther"},{"key":"1256_CR39","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/ecco-jcc\/jjw085","volume":"10","author":"K Farkas","year":"2016","unstructured":"Farkas K, Rutka M, Golovics PA, et al. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis. 2016;10:1273\u20138.","journal-title":"J Crohns Colitis"},{"key":"1256_CR40","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/14712598.2018.1530758","volume":"18","author":"A Balint","year":"2018","unstructured":"Balint A, Rutka M, Kolar M, et al. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis\u2014results from multicenter observational cohort. Expert Opin Biol Ther. 2018;18:1181\u20137.","journal-title":"Expert Opin Biol Ther"},{"key":"1256_CR41","first-page":"313","volume":"63","author":"A Tursi","year":"2017","unstructured":"Tursi A, Allegretta L, Chiri S, et al. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real-life experience in IBD primary centers. Minerva Gastroenterol Dietol. 2017;63:313\u20138.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"1256_CR42","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies\u2014non-clinical and clinical issues. 2014; http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR43","first-page":"21","volume":"8","author":"E Doevendans","year":"2019","unstructured":"Doevendans E, Schellekens H. Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies (Basel, Switzerland). 2019;8:21.","journal-title":"Antibodies (Basel, Switzerland)"},{"key":"1256_CR44","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/rheumatology\/kex434","volume":"57","author":"M Jani","year":"2018","unstructured":"Jani M, Dixon WG, Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology (Oxford). 2018;57:1896\u2013907.","journal-title":"Rheumatology (Oxford)"},{"key":"1256_CR45","unstructured":"US Food and Drug Administration. Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for anti-drug antibody detection. 2019; https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug. Accessed 17 Dec 2019."},{"key":"1256_CR46","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins. 2017; https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/1744666X.2015.1090312","volume":"11","author":"JS Kim","year":"2015","unstructured":"Kim JS, Kim SH, Kwon B, et al. Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13). Expert Rev Clin Immunol. 2015;11:33\u201341.","journal-title":"Expert Rev Clin Immunol"},{"key":"1256_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2217\/fon-2018-0553","volume":"15","author":"T Schreitm\u00fcller","year":"2019","unstructured":"Schreitm\u00fcller T, Barton B, Zharkov A, et al. Comparative immunogenicity assessment of biosimilars. Future Oncol. 2019;15:319\u201329.","journal-title":"Future Oncol"},{"key":"1256_CR49","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/cei.13112","volume":"192","author":"B Gorovits","year":"2018","unstructured":"Gorovits B, Baltrukonis DJ, Bhattacharya I, et al. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol. 2018;192:348\u201365.","journal-title":"Clin Exp Immunol"},{"key":"1256_CR50","doi-asserted-by":"crossref","unstructured":"Vermeire S, Gils A, Accossato P, et al. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol 2018;11:1756283x17750355.","DOI":"10.1177\/1756283X17750355"},{"key":"1256_CR51","doi-asserted-by":"publisher","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","volume":"22","author":"U Billmeier","year":"2016","unstructured":"Billmeier U, Dieterich W, Neurath MF, et al. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22:9300\u201313.","journal-title":"World J Gastroenterol"},{"key":"1256_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","volume":"2","author":"MD Cohen","year":"2015","unstructured":"Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015;2:99\u2013111.","journal-title":"Rheumatol Ther"},{"key":"1256_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.imlet.2017.05.010","volume":"189","author":"B Nakken","year":"2017","unstructured":"Nakken B, Papp G, Bosnes V, et al. Biomarkers for rheumatoid arthritis: from molecular processes to diagnostic applications-current concepts and future perspectives. Immunol Lett. 2017;189:13\u20138.","journal-title":"Immunol Lett"},{"key":"1256_CR54","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1634\/theoncologist.2017-0671","volume":"23","author":"E Cazap","year":"2018","unstructured":"Cazap E, Jacobs I, McBride A, et al. Global acceptance of biosimilars: importance of regulatory consistency, education, and trust. Oncologist. 2018;23:1188\u201398.","journal-title":"Oncologist"},{"key":"1256_CR55","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","volume":"114","author":"CF Kirchhoff","year":"2017","unstructured":"Kirchhoff CF, Wang XM, Conlon HD, et al. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114:2696\u2013705.","journal-title":"Biotechnol Bioeng"},{"key":"1256_CR56","unstructured":"Swissmedic. Guidance document authorisation biosimilar HMV4. 2019; https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/legal\/legal-basis\/administrative-ordinances.html. Accessed 17 Dec 2019."},{"key":"1256_CR57","unstructured":"Health Canada. Guidance document: information and submission requirements for biosimilar biologic drugs. 2016; https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs-1.html. Accessed 17 Dec 2019."},{"key":"1256_CR58","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3109\/14397595.2015.1022297","volume":"25","author":"T Takeuchi","year":"2015","unstructured":"Takeuchi T, Yamanaka H, Tanaka Y, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25:817\u201324.","journal-title":"Mod Rheumatol"},{"key":"1256_CR59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","volume":"27","author":"Y Tanaka","year":"2017","unstructured":"Tanaka Y, Yamanaka H, Takeuchi T, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27:237\u201345.","journal-title":"Mod Rheumatol"},{"key":"1256_CR60","unstructured":"European Medicines Agency. Tailored scientific advice to support step-by-step development of new biosimilars. News 16\/12\/2016; https:\/\/www.ema.europa.eu\/en\/news\/tailored-scientific-advice-support-step-step-development-new-biosimilars. Accessed 17 Dec 2019."},{"key":"1256_CR61","unstructured":"European Medicines Agency. Tailored scientific advice to support step-by-step development of new biosimilars 2018; https:\/\/www.ema.europa.eu\/en\/documents\/other\/tailored-scientific-advice-support-step-step-development-new-biosimilars_en.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR62","unstructured":"US Food and Drug Administration. Formal meetings between the FDA and sponsors or applicants of BsUFA products: guidance for industry (draft guidance). 2018; https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/formal-meetings-between-fda-and-sponsors-or-applicants-bsufa-products-guidance-industry. Accessed 17 Dec 2019."},{"key":"1256_CR63","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/2042098618790442","volume":"9","author":"B Calvo","year":"2018","unstructured":"Calvo B, Martinez-Gorostiaga J, Echevarria E. The surge in biosimilars: considerations for effective pharmacovigilance and EU regulation. Ther Adv Drug Saf. 2018;9:601\u20138.","journal-title":"Ther Adv Drug Saf"},{"key":"1256_CR64","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.2147\/DDDT.S75219","volume":"9","author":"E Li","year":"2015","unstructured":"Li E, Subramanian J, Anderson S, et al. Development of biosimilars in an era of oncologic drug shortages. Drug Des Devel Ther. 2015;9:3247\u201355.","journal-title":"Drug Des Devel Ther"},{"key":"1256_CR65","unstructured":"European Comission. Rules governing medicinal products in the European Union: Guidelines on pharmacovigilance for medicinal products for human use. 2008; https:\/\/ec.europa.eu\/health\/\/sites\/health\/files\/files\/eudralex\/vol-9\/pdf\/vol9a_09-2008_en.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR66","unstructured":"US Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS). 2018; https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/risk-evaluation-and-mitigation-strategies-rems. Accessed 17 Dec 2019."},{"key":"1256_CR67","unstructured":"US Food and Drug Administration. 21st Century Cures Act. 2018; https:\/\/www.fda.gov\/RegulatoryInformation\/LawsEnforcedbyFDA\/SignificantAmendmentstotheFDCAct\/21stCenturyCuresAct\/default.htm. Accessed 17 Dec 2019."},{"key":"1256_CR68","unstructured":"Gottlieb S. Submission to Congress: Food & Drug Administration work plan and proposed funding allocations of FDA innovation account. 2017; https:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/LawsEnforcedbyFDA\/SignificantAmendmentstotheFDCAct\/21stCenturyCuresAct\/UCM562852.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR69","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR70","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/1756-185X.12754","volume":"18","author":"CS Lau","year":"2015","unstructured":"Lau CS, Chia F, Harrison A, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis. 2015;18:685\u2013713.","journal-title":"Int J Rheum Dis"},{"key":"1256_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1256_CR72","unstructured":"National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. 2018; https:\/\/www.nice.org.uk\/guidance\/ng100\/resources\/rheumatoid-arthritis-in-adults-management-pdf-66141531233989. Accessed 17 Dec 2019."},{"key":"1256_CR73","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/rheumatology\/keq006a","volume":"49","author":"C Deighton","year":"2010","unstructured":"Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford). 2010;49:1197\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"1256_CR74","doi-asserted-by":"crossref","unstructured":"Cardiel MH, Latin American Rheumatology Associations of the Pan-American League of Associations for R, and Grupo Latinoamericano de Estudio de Artritis R. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford) 2006;45 Suppl 2:ii7\u2013ii22.","DOI":"10.1093\/rheumatology\/kei500"},{"key":"1256_CR75","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","volume":"22","author":"CS Lau","year":"2019","unstructured":"Lau CS, Chia F, Dans L, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22:357\u201375.","journal-title":"Int J Rheum Dis"},{"key":"1256_CR76","unstructured":"National Institute for Health and Care Excellence. Drug treatment for rheumatoid arthritis. 2019; https:\/\/pathways.nice.org.uk\/pathways\/rheumatoid-arthritis#path=view%3A\/pathways\/rheumatoid-arthritis\/drug-treatment-for-rheumatoid-arthritis.xml&content=view-index. Accessed 17 Dec 2019."},{"key":"1256_CR77","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","volume":"77","author":"SA Bergstra","year":"2018","unstructured":"Bergstra SA, Branco JC, Vega-Morales D, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis. 2018;77:1413.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"1256_CR78","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1586\/1744666X.2015.1090313","volume":"11","author":"L Gulacsi","year":"2015","unstructured":"Gulacsi L, Brodszky V, Baji P, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol. 2015;11(Suppl 1):S43\u201352.","journal-title":"Expert Rev Clin Immunol"},{"key":"1256_CR79","doi-asserted-by":"publisher","first-page":"1345580","DOI":"10.1080\/20016689.2017.1345580","volume":"5","author":"Z Kalo","year":"2017","unstructured":"Kalo Z, Voko Z, Ostor A, et al. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J Mark Access Health Policy. 2017;5:1345580.","journal-title":"J Mark Access Health Policy"},{"key":"1256_CR80","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198\u2013206.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR81","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2019.00279","volume":"10","author":"DC Baumgart","year":"2019","unstructured":"Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279.","journal-title":"Front Pharmacol"},{"key":"1256_CR82","unstructured":"Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth? Ann Rheum Dis. 2014;73:2010\u201321."},{"key":"1256_CR83","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/keq178","volume":"49","author":"PG Conaghan","year":"2010","unstructured":"Conaghan PG, Hensor EMA, Keenan A-M, et al. Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. Rheumatology. 2010;49:1894\u20139.","journal-title":"Rheumatology"},{"key":"1256_CR84","first-page":"24","volume":"35","author":"F Ceccarelli","year":"2017","unstructured":"Ceccarelli F, Massafra U, Perricone C, et al. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE). Clin Exp Rheumatol. 2017;35:24\u201332.","journal-title":"Clin Exp Rheumatol"},{"key":"1256_CR85","doi-asserted-by":"publisher","first-page":"14479","DOI":"10.3748\/wjg.v20.i39.14479","volume":"20","author":"R Fan","year":"2014","unstructured":"Fan R, Zhong J, Wang ZT, et al. Evaluation of \u201ctop-down\u201d treatment of early Crohn\u2019s disease by double balloon enteroscopy. World J Gastroenterol. 2014;20:14479\u201387.","journal-title":"World J Gastroenterol"},{"key":"1256_CR86","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/ecco-jcc\/jjx085","volume":"11","author":"T Hibi","year":"2017","unstructured":"Hibi T, Panaccione R, Katafuchi M, et al. The 5C concept and 5S principles in inflammatory bowel disease management. J Crohns Colitis. 2017;11:1302\u20138.","journal-title":"J Crohns Colitis"},{"key":"1256_CR87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3904\/kjim.2017.400","volume":"33","author":"JP Im","year":"2018","unstructured":"Im JP, Ye BD, Kim YS, et al. Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med. 2018;33:28\u201335.","journal-title":"Korean J Intern Med"},{"key":"1256_CR88","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324\u201338.","journal-title":"Am J Gastroenterol"},{"key":"1256_CR89","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11938-013-0008-1","volume":"12","author":"BP Vaughn","year":"2014","unstructured":"Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Opt Gastroenterol. 2014;12:103\u201317.","journal-title":"Curr Treat Opt Gastroenterol"},{"key":"1256_CR90","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.crohns.2014.02.025","volume":"8","author":"GR D\u2019Haens","year":"2014","unstructured":"D\u2019Haens GR, Sartor RB, Silverberg MS, et al. Future directions in inflammatory bowel disease management. J Crohns Colitis. 2014;8:726\u201334.","journal-title":"J Crohns Colitis"},{"key":"1256_CR91","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477\u201383.","DOI":"10.1016\/j.crohns.2011.06.009"},{"key":"1256_CR92","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1136\/gutjnl-2011-300934","volume":"60","author":"I Ordas","year":"2011","unstructured":"Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn\u2019s disease: time for a change. Gut. 2011;60:1754\u201363.","journal-title":"Gut"},{"key":"1256_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5223\/pghn.2018.21.1.1","volume":"21","author":"B Kang","year":"2018","unstructured":"Kang B, Choe YH. Early biologic treatment in pediatric Crohn\u2019s disease: catching the therapeutic window of opportunity in early disease by treat-to-target. Pediatr Gastroenterol Hepatol Nutr. 2018;21:1\u201311.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"1256_CR94","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.crohns.2014.02.021","volume":"8","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014;8:927\u201335.","journal-title":"J Crohns Colitis"},{"key":"1256_CR95","first-page":"413","volume":"31","author":"JJ Tsui","year":"2018","unstructured":"Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn\u2019s disease? Ann Gastroenterol. 2018;31:413\u201324.","journal-title":"Ann Gastroenterol"},{"key":"1256_CR96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomollon","year":"2017","unstructured":"Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3\u201325.","journal-title":"J Crohns Colitis"},{"key":"1256_CR97","doi-asserted-by":"crossref","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017;11:769\u201384.","DOI":"10.1093\/ecco-jcc\/jjx009"},{"key":"1256_CR98","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571\u2013607.","journal-title":"Gut"},{"key":"1256_CR99","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol"},{"key":"1256_CR100","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1155\/2009\/201430","volume":"23","author":"DC Sadowski","year":"2009","unstructured":"Sadowski DC, Bernstein CN, Bitton A, et al. Canadian Association of Gastroenterology clinical practice guidelines: the use of tumour necrosis factor-alpha antagonist therapy in Crohn\u2019s disease. Can J Gastroenterol. 2009;23:185\u2013202.","journal-title":"Can J Gastroenterol"},{"key":"1256_CR101","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","volume":"148","author":"B Bressler","year":"2015","unstructured":"Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035\u20131058.e3.","journal-title":"Gastroenterology"},{"key":"1256_CR102","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","volume":"53","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305\u201353.","journal-title":"J Gastroenterol"},{"key":"1256_CR103","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ajg.2010.392","volume":"106","author":"GR D\u2019Haens","year":"2011","unstructured":"D\u2019Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199\u2013212.","journal-title":"Am J Gastroenterol"},{"key":"1256_CR104","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/MOG.0b013e3283622914","volume":"29","author":"PB Allen","year":"2013","unstructured":"Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29:397\u2013404.","journal-title":"Curr Opin Gastroenterol"},{"key":"1256_CR105","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/ecco-jcc\/jjy021","volume":"12","author":"B Kang","year":"2018","unstructured":"Kang B, Choi SY, Choi YO, et al. Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn\u2019s disease patients treated with combined immunosuppressive therapy. J Crohns Colitis. 2018;12:644\u201352.","journal-title":"J Crohns Colitis"},{"key":"1256_CR106","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/ecco-jcc\/jjw086","volume":"10","author":"B Kang","year":"2016","unstructured":"Kang B, Choi SY, Kim HS, et al. Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn\u2019s disease under combined immunosuppression: escalation versus early treatment. J Crohns Colitis. 2016;10:1279\u201386.","journal-title":"J Crohns Colitis"},{"key":"1256_CR107","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5223\/pghn.2012.15.4.243","volume":"15","author":"YS Lee","year":"2012","unstructured":"Lee YS, Baek SH, Kim MJ, et al. Efficacy of early infliximab treatment for pediatric Crohn\u2019s disease: a three-year follow-up. Pediatr Gastroenterol Hepatol Nutr. 2012;15:243\u20139.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"1256_CR108","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","volume":"7","author":"S Schreiber","year":"2013","unstructured":"Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3\u00a0years for adalimumab-treated patients with early Crohn\u2019s disease. J Crohns Colitis. 2013;7:213\u201321.","journal-title":"J Crohns Colitis"},{"key":"1256_CR109","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2018","unstructured":"Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779\u201389.","journal-title":"Lancet"},{"key":"1256_CR110","doi-asserted-by":"publisher","first-page":"e0177479","DOI":"10.1371\/journal.pone.0177479","volume":"12","author":"EH Oh","year":"2017","unstructured":"Oh EH, Oh K, Han M, et al. Early anti-TNF\/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn\u2019s disease with poor prognostic factors. PLoS One. 2017;12:e0177479.","journal-title":"PLoS One"},{"key":"1256_CR111","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/ibd.22925","volume":"18","author":"DT Rubin","year":"2012","unstructured":"Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn\u2019s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012;18:2225\u201331.","journal-title":"Inflamm Bowel Dis"},{"key":"1256_CR112","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/ajg.2010.78","volume":"105","author":"S Schreiber","year":"2010","unstructured":"Schreiber S, Colombel J-F, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn\u2019s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574\u201382.","journal-title":"Am J Gastroenterol"},{"key":"1256_CR113","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/apt.13251","volume":"42","author":"WJ Sandborn","year":"2015","unstructured":"Sandborn WJ, Melmed GY, McGovern DPB, et al. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn\u2019s disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015;42:330\u201342.","journal-title":"Aliment Pharmacol Ther"},{"issue":"130\u20138","key":"1256_CR114","first-page":"e7","volume":"17","author":"BG Feagan","year":"2018","unstructured":"Feagan BG, Lasch K, Lissoos T, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;17(130\u20138):e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"229\u201339","key":"1256_CR115","first-page":"e5","volume":"15","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(229\u201339):e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1256_CR116","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","volume":"23","author":"BE Sands","year":"2017","unstructured":"Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23:97\u2013106.","journal-title":"Inflamm Bowel Dis"},{"key":"1256_CR117","first-page":"741","volume":"12","author":"S Paramsothy","year":"2016","unstructured":"Paramsothy S, Cleveland NK, Zmeter N, et al. The role of biosimilars in inflammatory bowel disease. Gastroenterol Hepatol. 2016;12:741\u201351.","journal-title":"Gastroenterol Hepatol"},{"key":"1256_CR118","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11926-018-0769-6","volume":"20","author":"S Zhao","year":"2018","unstructured":"Zhao S, Chadwick L, Mysler E, et al. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20:57.","journal-title":"Curr Rheumatol Rep"},{"key":"1256_CR119","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/JIR.S165330","volume":"11","author":"P Rawla","year":"2018","unstructured":"Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215\u201326.","journal-title":"J Inflamm Res"},{"key":"1256_CR120","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304\u201316.","journal-title":"Lancet"},{"key":"1256_CR121","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/DDDT.S109852","volume":"11","author":"T Gabbani","year":"2017","unstructured":"Gabbani T, Deiana S, Annese V. CT-P13: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:1653\u201361.","journal-title":"Drug Des Devel Ther"},{"key":"1256_CR122","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/jgh.14645","volume":"34","author":"NH Kim","year":"2019","unstructured":"Kim NH, Lee JH, Hong SN, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2019;34:1523\u201332.","journal-title":"J Gastroenterol Hepatol"},{"key":"1256_CR123","doi-asserted-by":"publisher","first-page":"175628481984274","DOI":"10.1177\/1756284819842748","volume":"12","author":"\u00c1 Milassin","year":"2019","unstructured":"Milassin \u00c1, F\u00e1bi\u00e1n A, Moln\u00e1r T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Ther Adv Gastroenterol. 2019;12:1756284819842748.","journal-title":"Ther Adv Gastroenterol"},{"key":"1256_CR124","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1097\/MIB.0000000000001237","volume":"23","author":"L Gonczi","year":"2017","unstructured":"Gonczi L, Gecse KB, Vegh Z, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis. 2017;23:1908\u201315.","journal-title":"Inflamm Bowel Dis"},{"key":"1256_CR125","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2015-208914","volume":"76","author":"P Kaur","year":"2017","unstructured":"Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76:526\u201333.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR126","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/13543784.2016.1255724","volume":"25","author":"C Wynne","year":"2016","unstructured":"Wynne C, Altendorfer M, Sonderegger I, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE\u00ae-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25:1361\u201370.","journal-title":"Expert Opin Investig Drugs"},{"key":"1256_CR127","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jcpt.12583","volume":"42","author":"D Shin","year":"2017","unstructured":"Shin D, Lee Y, Kim H, et al. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42:672\u20138.","journal-title":"J Clin Pharm Ther"},{"key":"1256_CR128","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76:1679\u201387.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR129","first-page":"914","volume":"77","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77:914\u201321.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR130","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.40336","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70:40\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"1256_CR131","doi-asserted-by":"publisher","first-page":"e0119683","DOI":"10.1371\/journal.pone.0119683","volume":"10","author":"JT Joensuu","year":"2015","unstructured":"Joensuu JT, Huoponen S, Aaltonen KJ, et al. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10:e0119683.","journal-title":"PLoS One"},{"key":"1256_CR132","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2471\/BLT.16.187344","volume":"95","author":"A Ferrario","year":"2017","unstructured":"Ferrario A, Humbert T, Kanavos P, et al. Strategic procurement and international collaboration to improve access to medicines. Bull World Health Organ. 2017;95:720\u20132.","journal-title":"Bull World Health Organ"},{"key":"1256_CR133","first-page":"289","volume":"11","author":"M Severs","year":"2017","unstructured":"Severs M, Oldenburg B, van Bodegraven AA, et al. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017;11:289\u201396.","journal-title":"J Crohns Colitis"},{"key":"1256_CR134","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/0929867324666170406112304","volume":"26","author":"L Gulacsi","year":"2019","unstructured":"Gulacsi L, Pentek M, Rencz F, et al. Biosimilars for the management of inflammatory bowel diseases: economic considerations. Curr Med Chem. 2019;26:259\u201369.","journal-title":"Curr Med Chem"},{"key":"1256_CR135","doi-asserted-by":"publisher","first-page":"S461","DOI":"10.1093\/ecco-jcc\/jjx180.819","volume":"12","author":"JF Colombel","year":"2018","unstructured":"Colombel JF, Ungaro R, Aggarwal S, et al. P692 Efficacy and safety of early biologic treatment of Crohn\u2019s disease in adult and paediatric patients: a systematic review. J Crohns Colitis. 2018;12:S461.","journal-title":"J Crohns Colitis"},{"key":"1256_CR136","doi-asserted-by":"publisher","first-page":"S074","DOI":"10.1093\/ecco-jcc\/jjx180.102","volume":"1","author":"R Panaccione","year":"2018","unstructured":"Panaccione R, Colombel JF, Bossuyt P, et al. Long-term cost-effectiveness of tight control for Crohn\u2019s disease with adalimumab-based treatment: economic evaluation beyond 48\u00a0weeks of CALM trial. J Crohns Colitis. 2018;1:S074\u20135.","journal-title":"J Crohns Colitis"},{"key":"1256_CR137","doi-asserted-by":"publisher","first-page":"e0185500","DOI":"10.1371\/journal.pone.0185500","volume":"12","author":"N Pillai","year":"2017","unstructured":"Pillai N, Dusheiko M, Burnand B, et al. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500.","journal-title":"PLoS One"},{"key":"1256_CR138","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.20716","volume":"52","author":"K Puolakka","year":"2005","unstructured":"Puolakka K, Kautiainen H, M\u00f6tt\u00f6nen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52:36\u201341.","journal-title":"Arthritis Rheum"},{"key":"1256_CR139","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/rheumatology\/kep239","volume":"48","author":"A Anis","year":"2009","unstructured":"Anis A, Zhang W, Emery P, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology. 2009;48:1283\u20139.","journal-title":"Rheumatology"},{"key":"1256_CR140","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3747\/co.26.4395","volume":"26","author":"WY Cheung","year":"2019","unstructured":"Cheung WY, Kornelsen EA, Mittmann N, et al. The economic impact of the transition from branded to generic oncology drugs. Curr Oncol. 2019;26:89\u201393.","journal-title":"Curr Oncol"},{"key":"1256_CR141","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1517\/13543784.2016.1126247","volume":"25","author":"M Berns","year":"2016","unstructured":"Berns M, Hommes DW. Anti-TNF-alpha therapies for the treatment of Crohn\u2019s disease: the past, present and future. Expert Opin Investig Drugs. 2016;25:129\u201343.","journal-title":"Expert Opin Investig Drugs"},{"key":"1256_CR142","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s12325-015-0233-1","volume":"32","author":"A Jha","year":"2015","unstructured":"Jha A, Upton A, Dunlop WC, et al. The budget impact of biosimilar infliximab (Remsima\u00ae) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32:742\u201356.","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"1256_CR143","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1007\/s10198-014-0595-3","volume":"15","author":"V Brodszky","year":"2014","unstructured":"Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65\u201371.","journal-title":"Eur J Health Econ"},{"key":"1256_CR144","unstructured":"Simon Kucher & Partners. Payers\u2019 price & market access policies supporting a sustainable biosimilar medicines market. 2016; https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/09\/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication2.pdf. Accessed 17 Dec 2019."},{"key":"1256_CR145","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.clinthera.2016.02.023","volume":"38","author":"M Khraishi","year":"2016","unstructured":"Khraishi M, Stead D, Lukas M, et al. Biosimilars: a multidisciplinary perspective. Clin Ther. 2016;38:1238\u201349.","journal-title":"Clin Ther"},{"key":"1256_CR146","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3748\/wjg.v23.i11.1932","volume":"23","author":"MK Zheng","year":"2017","unstructured":"Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol. 2017;23:1932\u201343.","journal-title":"World J Gastroenterol"},{"key":"1256_CR147","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.14368","volume":"46","author":"N Mitrev","year":"2017","unstructured":"Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46:1037\u201353.","journal-title":"Aliment Pharmacol Ther"},{"key":"1256_CR148","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","volume":"13","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Juncadella A, Wong D, et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019;13:976\u201381.","journal-title":"J Crohns Colitis"},{"issue":"suppl 1","key":"1256_CR149","first-page":"A102","volume":"5","author":"W Reinisch","year":"2017","unstructured":"Reinisch W, Eser A, Schreiber S, et al. Body weight and rapid clearance determine early formation of anti-drug antibodies against infliximab. United European Gastroenterol J. 2017;5(suppl 1):A102.","journal-title":"United European Gastroenterol J"},{"key":"1256_CR150","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/ecco-jcc\/jjy109","volume":"12","author":"A Ricciuto","year":"2018","unstructured":"Ricciuto A, Dhaliwal J, Walters TD, et al. Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis. J Crohns Colitis. 2018;12:1302\u201315.","journal-title":"J Crohns Colitis"},{"key":"1256_CR151","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/ibd\/izy069","volume":"24","author":"X Roblin","year":"2018","unstructured":"Roblin X, Riviere P, Flamant M, et al. Proactive therapeutic drug monitoring of TNF antagonists in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:1904\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1256_CR152","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1053\/j.gastro.2015.04.024","volume":"148","author":"S Ben-Horin","year":"2015","unstructured":"Ben-Horin S. Drug level-based anti-tumor necrosis factor therapy: ready for prime time? Gastroenterology. 2015;148:1268\u201371.","journal-title":"Gastroenterology"},{"key":"1256_CR153","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00535-016-1266-1","volume":"52","author":"L Martelli","year":"2017","unstructured":"Martelli L, Olivera P, Roblin X, et al. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017;52:19\u201325.","journal-title":"J Gastroenterol"},{"key":"1256_CR154","unstructured":"NHS Improvement. The NHS saves \u00a3324 million in a year by switching to better value medicines. 2018; https:\/\/improvement.nhs.uk\/news-alerts\/nhs-saves-324-million-year-switching-better-value-medicines\/. Accessed 17 Dec 2019."},{"key":"1256_CR155","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40259-017-0252-3","volume":"31","author":"MI Aladul","year":"2017","unstructured":"Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31:533\u201344.","journal-title":"BioDrugs"},{"key":"1256_CR156","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000449088","volume":"35","author":"J Jahnsen","year":"2017","unstructured":"Jahnsen J, Kaasen Jorgensen K. Experience with biosimilar infliximab (Remsima\u00ae) in Norway. Dig Dis. 2017;35:83\u201390.","journal-title":"Dig Dis"},{"key":"1256_CR157","first-page":"119","volume":"12","author":"P Lakatos","year":"2016","unstructured":"Lakatos P. European experience of infliximab biosimilars for the treatment of inflammatory bowel disease. Gastroenterol Hepatol. 2016;12:119\u201321.","journal-title":"Gastroenterol Hepatol"},{"key":"1256_CR158","unstructured":"Generics and Biosimilars Initiative. France aims to reach 80% biosimilar penetration by 2022. 2018; http:\/\/www.gabionline.net\/Policies-Legislation\/France-aims-to-reach-80-biosimilar-penetration-by-2022. Accessed 17 Dec 2019."},{"key":"1256_CR159","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","volume":"11","author":"S Danese","year":"2017","unstructured":"Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017;11:26\u201334.","journal-title":"J Crohns Colitis"},{"key":"1256_CR160","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355\u201363.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR161","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s12325-019-00998-3","volume":"36","author":"Y Liu","year":"2019","unstructured":"Liu Y, Yang M, Garg V, et al. Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review. Adv Ther. 2019;36:1851\u201377.","journal-title":"Adv Ther"},{"key":"1256_CR162","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-019-00346-5","volume":"33","author":"E Moorkens","year":"2019","unstructured":"Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: part 2-biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33:299\u2013306.","journal-title":"BioDrugs"},{"key":"1256_CR163","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nrgastro.2017.86","volume":"14","author":"S Danese","year":"2017","unstructured":"Danese S, Peyrin-Biroulet L. IBD: to switch or not to switch: that is the biosimilar question. Nat Rev Gastroenterol Hepatol. 2017;14:508\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1256_CR164","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apt.14997","volume":"49","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lam G, Ma C, et al. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49:31\u201340.","journal-title":"Aliment Pharmacol Ther"},{"key":"1256_CR165","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bjd.16890","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179:623\u201331.","journal-title":"Br J Dermatol"},{"key":"1256_CR166","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/jdv.14605","volume":"32","author":"S Gerdes","year":"2018","unstructured":"Gerdes S, Tha\u00e7i D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32:420\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1256_CR167","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/ecco-jcc\/jjy020","volume":"12","author":"K Kemp","year":"2018","unstructured":"Kemp K, Dibley L, Chauhan U, et al. Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn\u2019s disease or ulcerative colitis. J Crohns Colitis. 2018;12:760\u201376.","journal-title":"J Crohns Colitis"},{"key":"1256_CR168","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/ecco-jcc\/jjw138","volume":"11","author":"L Peyrin-Biroulet","year":"2017","unstructured":"Peyrin-Biroulet L, Lonnfors S, Roblin X, et al. Patient perspectives on biosimilars: a survey by the European Federation of Crohn\u2019s and Ulcerative Colitis Associations. J Crohns Colitis. 2017;11:128\u201333.","journal-title":"J Crohns Colitis"},{"key":"1256_CR169","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40259-017-0244-3","volume":"31","author":"E van Overbeeke","year":"2017","unstructured":"van Overbeeke E, De Beleyr B, de Hoon J, et al. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs. 2017;31:447\u201359.","journal-title":"BioDrugs"},{"key":"1256_CR170","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40259-017-0238-1","volume":"31","author":"MI Aladul","year":"2017","unstructured":"Aladul MI, Fitzpatrick RW, Chapman SR. Patients\u2019 understanding and attitudes towards infliximab and etanercept biosimilars: result of a UK web-based survey. BioDrugs. 2017;31:439\u201346.","journal-title":"BioDrugs"},{"key":"1256_CR171","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/03007995.2018.1560221","volume":"35","author":"A Teeple","year":"2019","unstructured":"Teeple A, Ginsburg S, Howard L, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35:603\u20139.","journal-title":"Curr Med Res Opin"},{"key":"1256_CR172","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","volume":"32","author":"LE Kristensen","year":"2018","unstructured":"Kristensen LE, Alten R, Puig L, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32:397\u2013404.","journal-title":"BioDrugs"},{"key":"1256_CR173","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5114\/reum.2018.77975","volume":"56","author":"P Wiland","year":"2018","unstructured":"Wiland P, Batko B, Brzosko M, et al. Biosimilar switching\u2014current state of knowledge. Reumatologia. 2018;56:234\u201342.","journal-title":"Reumatologia"},{"key":"1256_CR174","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/1744666X.2018.1512406","volume":"14","author":"L Pouillon","year":"2018","unstructured":"Pouillon L, Socha M, Demore B, et al. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018;14:739\u201349.","journal-title":"Expert Rev Clin Immunol"},{"key":"1256_CR175","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","volume":"85","author":"M Scherlinger","year":"2018","unstructured":"Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018;85:561\u20137.","journal-title":"Joint Bone Spine"},{"key":"1256_CR176","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00228-018-2418-4","volume":"74","author":"NW Boone","year":"2018","unstructured":"Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74:655\u201361.","journal-title":"Eur J Clin Pharmacol"},{"key":"1256_CR177","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40744-017-0085-z","volume":"4","author":"MF Rezk","year":"2017","unstructured":"Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther. 2017;4:209\u201318.","journal-title":"Rheumatol Ther"},{"key":"1256_CR178","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.2196\/jmir.4333","volume":"17","author":"J Laugesen","year":"2015","unstructured":"Laugesen J, Hassanein K, Yuan Y. The impact of internet health information on patient compliance: a research model and an empirical study. J Med Internet Res. 2015;17:e143.","journal-title":"J Med Internet Res"},{"key":"1256_CR179","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1200\/JCO.2017.77.4893","volume":"36","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36:1260\u20135.","journal-title":"J Clin Oncol"},{"key":"1256_CR180","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1007\/s12325-016-0431-5","volume":"33","author":"H Cohen","year":"2016","unstructured":"Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2016;33:2160\u201372.","journal-title":"Adv Ther"},{"key":"1256_CR181","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/PPA.S104891","volume":"10","author":"I Jacobs","year":"2016","unstructured":"Jacobs I, Singh E, Sewell KL, et al. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. 2016;10:937\u201348.","journal-title":"Patient Prefer Adherence"},{"key":"1256_CR182","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/fon-2017-0154","volume":"13","author":"WS Kim","year":"2017","unstructured":"Kim WS, Ogura M, Kwon H-C, et al. Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer. Future Oncol. 2017;13:17\u201329.","journal-title":"Future Oncol"},{"key":"1256_CR183","first-page":"102","volume":"25","author":"E Leonard","year":"2019","unstructured":"Leonard E, Wascovich M, Oskouei S, et al. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25:102\u201312.","journal-title":"J Manag Care Spec Pharm"},{"key":"1256_CR184","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.biologicals.2016.03.006","volume":"44","author":"J Braun","year":"2016","unstructured":"Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44:257\u201366.","journal-title":"Biologicals"},{"key":"1256_CR185","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/ecco-jcc\/jjw090","volume":"10","author":"S Danese","year":"2016","unstructured":"Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn\u2019s Colitis Organization [ECCO] members: an updated survey. J Crohns Colitis. 2016;10:1362\u20135.","journal-title":"J Crohns Colitis"},{"key":"1256_CR186","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76:346\u201354.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR187","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/annrheumdis-2016-210700","volume":"77","author":"R Westhovens","year":"2018","unstructured":"Westhovens R, Yoo DH, Jaworski J, et al. Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a phase I\/III randomised controlled trial [THU0191, presented at EULAR 2018]. Ann Rheum Dis. 2018;77:315.","journal-title":"Ann Rheum Dis"},{"key":"1256_CR188","doi-asserted-by":"crossref","unstructured":"Reinisch W, Jang BI, Borzan V, et al. A novel formulation of CTP13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomised controlled trial in patients with active Crohn\u2019s disease [abstract A1103, presented at ECCO 2019].","DOI":"10.1093\/ecco-jcc\/jjy222.096"},{"key":"1256_CR189","doi-asserted-by":"publisher","first-page":"S-1371","DOI":"10.1016\/S0016-5085(18)34477-9","volume":"154","author":"S Schreiber","year":"2018","unstructured":"Schreiber S, Jang BI, Borzan V, et al. Novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: Initial results from a phase I open-label randomized controlled trial in patients with active Crohn\u2019s disease. Gastroenterology. 2018;154:S-1371.","journal-title":"Gastroenterology"},{"key":"1256_CR190","unstructured":"US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: guidance for industry. 2019; https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-guidance-industry. Accessed 17 Dec 2019."}],"updated-by":[{"DOI":"10.1007\/s40265-020-01333-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01256-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01256-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01256-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:09:43Z","timestamp":1611878983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01256-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":190,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01256-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-020-01333-9","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"30 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The affiliation of the corresponding author Silvio Danese, which currently reads.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Celltrion Healthcare Co., Ltd provided funding for medical writing support for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"HK is employed by and holds stock options in Celltrion Healthcare Co., Ltd. LA has received financial support from Biogen for lectures; grants have been awarded to the European Federation of Crohn\u2019s & Ulcerative Colitis Associations (for projects, advocacy activities, surveys) from Atlantic, AbbVie, Biogen, Celgene, Celltrion, Merck-MSD, Ferring, Janssen, Mundipharma, Otsuka, Pfizer, Shire, Takeda, Vifor, and Philips Morris International Foundation. AD has served as consultant for AbbVie, Celgene, Janssen, MSD, Pfizer, Roche, Sandoz\/Hexal, Takeda, and Vifor; received payment for development of educational presentations from Falk Foundation, Ferring, Tillotts, and Takeda; received speaker fees from AbbVie, Falk Foundation, Ferring, Janssen, MSD, Pfizer, Vifor, and Takeda; received manuscript fees from Thieme and Wiley; and received research grants from Institut f\u00fcr Gemeinwohl and Stiftung Leben mit Krebs. FG has received financial support from AbbVie, Janssen, MSD, and Takeda for lectures and travel to scientific meetings. JH has received research grants from Janssen, MSD, and Takeda; served as a consultant and\/or an advisory board member for AbbVie, Celgene, Celltrion, Ferring, Hospira, Janssen, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Tillots Pharma, and Vifor Pharma; and served as a speaker for AbbVie, Celgene, Ferring, Hospira, Janssen, MSD, Novartis, Pfizer, Sandoz, Shire, Takeda, Tillotts Pharma, and Vifor Pharma. PMI has received honoraria for acting in an advisory capacity from AbbVie, Celgene, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Samsung Bioepis, Sandoz, Takeda, Topivert, VH2, Vifor, and Warner Chilcott; received speaker fees from AbbVie, Falk Pharma, Ferring, Janssen, MSD, Pfizer, Sandoz, Shire, Takeda, Tillotts, and Warner Chilcott; and received research funding from MSD, Pfizer, and Takeda. JJ has served as a speaker, consultant, or advisory board member for AbbVie, Astro Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Ferring, Hikma, Janssen, Meda, MSD, Napp Pharma, Orion Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts, and Sandoz. PLL has received consulting fees or lecture support from AbbVie, Celgene, Celltrion, Ferring, MSD, Pfizer, Roche, and Takeda and unrestricted research support from AbbVie, Pfizer, and Takeda. BP has received honoraria and speaker fees from AbbVie, AstraZeneca, Celltrion, GSK, Lilly, Pfizer, Roche, and UCB. LP-B has received consulting fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Enterome, Ferring, Genentech, Gilead, Index Pharmaceuticals, Janssen, Lilly, MSD, Nestle, Oppilan Pharma, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Tillotts, and Vifor; payment for lectures, including service on speakers bureaus, from AbbVie, Biogen, Celltrion, Ferring, Hikma, Janssen, MSD, Pfizer, Roche, Samsung Bioepis, Takeda, and Tillotts; grant\/research support from AbbVie, MSD, and Takeda; and stock options from CT-SCOUT. Stefan Schreiber has received personal fees for participation on advisory boards from AbbVie, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, IMAB, Falk, Fresenius, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Takeda, and Theravance. Steven Simoens has conducted biosimilar research sponsored by Hospira (now Pfizer); was involved in a stakeholder roundtable on biosimilars sponsored by Amgen, MSD, and Pfizer; has participated in an advisory board meeting for Pfizer; and currently works with Amgen, Celltrion, Mundipharma, and Pfizer as a consultant to carry out biosimilar research. RW has acted as a principal investigator and advisor for Celltrion and Galapagos\/Gilead and has given lectures for Celltrion. SD has received consulting fees or honorarium from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring Pharmaceuticals Inc., Gilead, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, and Pfizer. RA, KG, JHJ, JL, and SM have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}